Role of Melatonin as an Adjunctive Treatment for Depression and Cognitive Impairment in Hemodialysis Patients: A Randomized, Double-Blind Clinical Trial DOI Creative Commons

Shima Hatamkhani,

Sara Khanipour Roshan, Afshin Shiva

и другие.

Iranian Journal of Psychiatry, Год журнала: 2024, Номер unknown

Опубликована: Дек. 29, 2024

Objective: Chronic kidney disease (CKD) is a pervasive health issue associated with various complications, including cognitive impairment and depression among patients undergoing hemodialysis. This study aimed to assess the impact of melatonin on function in hemodialysis patients. Method : A randomized, double-blinded, placebo-controlled clinical trial was conducted 50 patients, half receiving 3 mg daily other placebo for two months. Depression were evaluated using Beck Inventory (BDI) Mini-Mental State Examination (MMSE) questionnaire, respectively. Quantitative variables analyzed t-test. The Chi-square test also qualitative variables. data by covariance analysis before after intervention. Results: Hypertension most prevalent underlying condition participants, affecting 40% intervention group. group exhibited baseline depressive symptoms (mean BDI score: 16.12 ± 7.12), which significantly improved post-intervention (13.6 6.6). Notably, both control groups demonstrated significant reductions symptoms, as assessed paired t-tests (P = 0.033 P 0.02, respectively). Cognitive function, measured MMSE, (1.28 0.81 melatonin, 1.52 0.1 placebo), within-group differences 0.048 0.002, ANCOVA revealed no between-group scores (F(1,47) 0.196, 0.66, partial eta-squared 0.004). MMSE 0.003, 0.954, 0.00) post-intervention. Conclusion: While this did not demonstrate effects positive changes observed, warranting further research optimize treatment regimens explore potential therapeutic benefits patient population.

Язык: Английский

Role of Melatonin as an Adjunctive Treatment for Depression and Cognitive Impairment in Hemodialysis Patients: A Randomized, Double-Blind Clinical Trial DOI Creative Commons

Shima Hatamkhani,

Sara Khanipour Roshan, Afshin Shiva

и другие.

Iranian Journal of Psychiatry, Год журнала: 2024, Номер unknown

Опубликована: Дек. 29, 2024

Objective: Chronic kidney disease (CKD) is a pervasive health issue associated with various complications, including cognitive impairment and depression among patients undergoing hemodialysis. This study aimed to assess the impact of melatonin on function in hemodialysis patients. Method : A randomized, double-blinded, placebo-controlled clinical trial was conducted 50 patients, half receiving 3 mg daily other placebo for two months. Depression were evaluated using Beck Inventory (BDI) Mini-Mental State Examination (MMSE) questionnaire, respectively. Quantitative variables analyzed t-test. The Chi-square test also qualitative variables. data by covariance analysis before after intervention. Results: Hypertension most prevalent underlying condition participants, affecting 40% intervention group. group exhibited baseline depressive symptoms (mean BDI score: 16.12 ± 7.12), which significantly improved post-intervention (13.6 6.6). Notably, both control groups demonstrated significant reductions symptoms, as assessed paired t-tests (P = 0.033 P 0.02, respectively). Cognitive function, measured MMSE, (1.28 0.81 melatonin, 1.52 0.1 placebo), within-group differences 0.048 0.002, ANCOVA revealed no between-group scores (F(1,47) 0.196, 0.66, partial eta-squared 0.004). MMSE 0.003, 0.954, 0.00) post-intervention. Conclusion: While this did not demonstrate effects positive changes observed, warranting further research optimize treatment regimens explore potential therapeutic benefits patient population.

Язык: Английский

Процитировано

0